European Patent Granted for Ibudilast Plus Interferon-Beta in MS Treatment

MediciNova has been granted a European patent for the use of ibudilast in combination with interferon-beta medications to treat progressive forms of multiple sclerosis (MS). The patent covers a wide range of doses, dosing frequency, and duration for both medications, as well as the use of the therapies simultaneously or consecutively. The patent protections will be valid until at least October 2039. Ibudilast has shown promising results in slowing brain volume loss and protecting nerve cells in clinical trials.